- About KeenMind
- Common Questions
- The Science
- Where to Find KeenMind
- Contact Us
An Acute, Double-Blind, Placebo-Controlled Crossover Study of 320 mg and 640 mg Doses of KeenMind CDRI 08™ on Sustained Cognitive Performance*
Abstract: Standardized extracts of the traditional Ayurvedic medicine Bacopa monnieri (Brahmi) have been recently shown to have cognitive enhancing effects in chronic administration studies. Pre-clinical work has also identified nootropic effects of Brahmi. There has, however, been little research on the acute effects of Brahmi on cognitive function.
Methods: The study aimed to assess the acute effects of KeenMind in a double-blind, placebo-controlled study in normal healthy participants who completed a cognitively demanding series of tests. Twenty-four healthy volunteers aged between 18 and 56 years completed six repetitions of the Cognitive Demand Battery (CDB) after consuming a placebo, KeenMind (2 capsules), or KeenMind (4 capsules) in a cross-over design and provided cardiovascular and mood assessments before and after treatment.
Results: Change from baseline scores indicated that the 2 capsule dose of KeenMind improved performance at the first, second, and fourth repetition post-dosing on the CDB, and the treatments had no effect upon cardiovascular activity or in attenuating task-induced ratings of stress and fatigue.
Conclusions: 2 capsules of KeenMind appear to have some acutely enhancing effects upon cognitive functioning even in healthy young individuals (i.e. a genuine nootropic effect). This effect did not appear to be dose related, but could possibly be occurring even earlier than the assessed pharmacological window. The nootropic effect seemed limited to aspects of reasoning and cognitive speed. It was concluded that assessment of an earlier pharmacological window and use of less memory-specific cognitive tests together with more temporally sensitive measures of brain activity may improve our understanding of the acute neurocognitive properties of KeenMind.
*Downey LA et al. 2012. An acute, double-blind, placebo-controlled crossover study of 320 mg and 640 mg doses of a special extract of Bacopa monnieri (CDRI 08™) on sustained cognitive performance. Phytother . Res., Published online DOI: 10.1002/ptr.4864.